Skip to main content

Breast.

63 studies recruiting right now, most recently updated first.

Open the Phase 2 page · a list of only those studies

Triangle is made by Triangle Health, Inc.

Breast63 studies

HR-Positive, HER2-Low or Ultralow Metastatic Breast CancerPhase 1/2NCT07198724

Elacestrant + Trastuzumab Deruxtecan

ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

Kristina A. FanucciOpen the brief

Triple Negative Breast CancerPhase 1NCT05504707Papers

HER2 - primed Dendritic cells

DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer

H. Lee Moffitt Cancer Center and Research InstituteOpen the brief

Triple-Negative Breast CancerPhase 1NCT06324240

Personalized TMV Tumor Vaccine

Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

Emory UniversityOpen the brief

Metastatic Hormone Receptor-Positive Breast CancerPhase 1NCT07137871

Avasopasem + CDK4/6 Inhibitor and Hormonal Therapy

Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy

The University of Texas Health Science Center at San AntonioOpen the brief

Clinical trials: Phase 1 and Phase 2, explained